BeWhere Holdings (BEW.V) on Tuesday said it requested exchange approval to launch a normal-course issuer bid to repurchase and cancel up to 5% of its shares over 12 months beginning June 9.
The company it will buy back up to 4.86-million shares over the period. On May 29, the number of issued and outstanding shares was 97.11-million. T
Shares of the company were up $0.01 at last look to $0.82 on the TSX Venture Exchange.
Price: $0.82, Change: $+0.01, Percent Change: +1.23%
Bullion Gold Resources (BGD.V) on Tuesday said it will raise up to $1.5 million in a private placement of share units.The company is seeking to place up to 16.67-million units priced at $0.09 and made up of a share and one half of an 18-month warrant to buy a share for $0.15.Proceeds will be used primarily to fund the validation drilling campaign at the Terragold project, together with related geological, technical and exploration activities, which are scheduled to begin in late June.The company's shares were last seen up $0.01 to $0.095 on the TSX Venture Exchange.Price: $0.10, Change: $+0.01, Percent Change: +11.76%
Golden Cross Resources (AUX.V) on Tuesday said it upsized a non-brokered private placement to $3.8 million up from its prior $3.0-million target.The company said it will not place 22.1-million units priced at $0.17 and made up of a share and one half of a two-year warrant to buy a share for $0.30.Proceeds will be used for exploration drilling and development of its Reedy Creek high-grade gold project in Australia and for general working capital and administrative needs.Shares of the company were last seen up $0.01 $0.185 on the TSX Venture Exchange.Price: $0.19, Change: $+0.01, Percent Change: +5.71%
Optimi Health (OPTI.CN), up 2.5% on last look, on Tuesday said it completed a production run of its 5mg psilocybin finished drug product.Optimi's 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, The company also updated the product's bottling configuration to improve ease of use for prescribers and patients in the Australian market, a statement said.Additional product from the same production run is earmarked to support upcoming clinical research in the United States and clinical trials in Europe across various indications, the company noted.Optimi Health said all stages of manufacturing were completed in-house and on-site at its facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The company is also authorized by Health Canada to hold up to 20 kilograms of psilocybin and approximately 2,000 kilograms of biomass on site, giving it commercial-scale supply capacity.Optimi Health shares were last seen up $0.20, to $8.10, on the Canadian Securities Exchange.Price: $8.10, Change: $+0.20, Percent Change: +2.53%